Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

SHEETSDecember 31, 2010 and 2009(In thousands of U.S. dollars, except share and per share amounts)December 31, 2010 December 31, 2009 (1)(unaudited)ASSETSCurrent assets:Cash and cash equivalents$

88,079$

167,171Short-term investments186,033133,506Accounts receivable, net86,57673,540Inventory109,69878,662Other current assets33,87414,848Total current assets504,260467,727Investment in BioMarin/Genzyme LLC1,082441Long-term investments128,171169,849Property, plant and equipment, net221,866199,141Intangible assets, net103,64840,977Goodwill53,36423,722Long-term deferred tax assets236,017-Other assets14,21515,306Total assets$

1,262,623$

917,163LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable and accrued liabilities$

83,632$

78,068Deferred revenue21286Total current liabilities83,84478,154Convertible debt377,521497,083Other long-term liabilities84,00119,741Total liabilities545,366594,978Stockholders’ equity:Common stock, $0.001 par value: 250,000,000 shares authorized at December 31, 2010 and 2009;
,634,465 and 100,961,922 shares issued and outstanding at December 31, 2010 and 2009,
respectively111101Additional paid-in capital1,090,188899,950Company common stock held by Nonqualified Deferred Compensation Plan(1,965)(1,715)Accumulated other comprehensive income (loss)188933Accumulated deficit(371,265)(577,084)Total stockholders’ equity717,257322,185Total liabilities and stockholders’ equity$

1,262,623$

917,163(1) December 31, 2009 balances were derived from the audited consolidated financial statements.BIOMARIN PHARMACEUTICAL INC.CONSOLIDATED STATEMENTS OF OPERATIONSFor the Three and Twelve Months Ended December 31, 2010 and 2009(In thousands, except for per share data)Three Months Ended December 31,Twelve Months Ended December 31,2010(unaudited)2009(unaudited)2010(unaudited)2009(1)REVENUES:Net product revenues$

98,477$

83,951$<
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
8. BioMarin Announces Third Quarter 2010 Financial Results
9. BioMarin to Host a Research and Development Day on October 19th
10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
11. BioMarin to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today ... from the Israeli patent office with claims for administering ... damage caused by an increase in blood flow, as ... after a blockage causing a heart attack or in ... can be caused to the heart attack or stroke ...
(Date:3/26/2015)... March 26, 2015  Flexpoint Sensor Systems, Inc. (OTCBB: ... it has received and shipped during the last 90 ... of interest in the sensors for gloves and medical ... have had custom sensors built for them. Some of ... custom sensors for medical rehab; a major international electronics ...
(Date:3/26/2015)... VEGAS , March 26, 2015 ... sales agreement with Radlink, Inc., an emerging global ... real-time image guidance with its hip replacement systems. ... commitment to help improve patient outcomes, increase patient ... conjunction with the 81st annual meeting of the ...
Breaking Medicine Technology:RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Flexpoint Sensor Systems, Inc. Expands Customer Base with New Orders of Sensors 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3
... Mylan Inc. (Nasdaq: MYL ) today ... entered into a settlement agreement with Warner Chilcott resolving ... as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 ... mg (28-Day Regimen). This medication is an oral contraceptive. ...
... NEW YORK, Oct. 19, 2011 Reportlinker.com announces ... in its catalogue: Syncria ... 2020 http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Forecasts to 2020 Summary ...
Cached Medicine Technology:Mylan Announces Femcon® Fe Settlement Agreement 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
(Date:3/26/2015)... March 26, 2015 Let’s not lose ... Fresh produce are today’s traffic magnets. Three out of ... because of their produce department, according to a Packaged ... as people are looking to add more fruits and ... Produce Manager® Day is April 2. As featured in ...
(Date:3/26/2015)... Alliance Healthcare Foundation (AHF), a nonprofit ... the poor and underserved in San Diego and Imperial ... $1 million award, the Innovation Initiative (i2). , ... round of our Innovation Initiative Award,” AHF Executive Director ... creative and ambitious projects in the past with this ...
(Date:3/26/2015)... UC Davis will establish a prestigious, leading-edge center ... A Silvio O. Conte Center for Basic or Translational ... the United States. , The center will be funded ... of Mental Health, which will allow UC Davis’ Conte ... of schizophrenia may be dysregulation of immune molecules that ...
(Date:3/26/2015)... March 26, 2015 Florida Hospital teamed up ... For Your Health campaign and live Dr. Oz event, which ... March 21st. More than a thousand people came out to ... living. , The world renowned cardiothoracic surgeon and Emmy ... Linda Hurtado and a panel of experts for the live ...
(Date:3/26/2015)... New York (PRWEB) March 26, 2015 ... to move forward nationwide, with the issuance of ... in Pennsylvania and Louisiana. According to an Order ... multidistrict litigation established for Xarelto injury claims in ... will now allow plaintiffs to file cases directly ...
Breaking Medicine News(10 mins):Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 3Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 4Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 2Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 3Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3
... , DENVER, July 14 Clinic Service Corporation (CSC), ... has secured an agreement to be the exclusive provider of medical ... , "This is another key new contract for us," ... and deep roots in the Littleton community. Our goal is to ...
... , , , , ... Hoyer, Chairman Henry Waxman, Chairman Charles Rangel, Chairman George Miller, Chairman John ... Capitol this afternoon to discuss legislation introduced today by the Tri-Committees on ... Below are the Speaker,s opening remarks and closing statement. A transcript ...
... , FLEMINGTON, N.J., July 14 A new national ... that the H1N1 Swine Flu poses some level of risk for a ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20071204/NYTU133LOGO ... conducted last night by HCD Research using its MediaCurves.com(R) website, and the ...
... , BEDFORD, N.H., July 14 Emerson Ecologics, ... Manager and Dr. Christine Toomasi has been named Professional Services Specialist. ... practitioner customers. , , Dr. ... Services team. Her enthusiasm, industry knowledge and experience in the ...
... , PHOENIX, July 14 Just weeks after the ... The World Egg Bank (TWEB) today announced a new loan program ... , Offered through Kansas-based Home National Bank, the program can ... or the total cost of an in vitro fertilization (IVF) procedure using fresh ...
... , WASHINGTON ., ... of the Congressional Urban Caucus, release d this statement ... the American Affordable Health Choices Act: , ... is the day that health care reform for all Americans begins its ...
Cached Medicine News:Health News:Pelosi Remarks at Press Conference on Introduction of Health Care Legislation 2Health News:Pelosi Remarks at Press Conference on Introduction of Health Care Legislation 3Health News:Physicians' Level of Concern for H1N1 Swine Flu Pandemic Highest Since April 2Health News:Physicians' Level of Concern for H1N1 Swine Flu Pandemic Highest Since April 3Health News:Emerson Ecologics Expands Their Team of Naturopathic Doctors 2Health News:New Fertility Financing for Donated Eggs Fills Void Left by Capital One 2Health News:Urban Caucus Chair Says Healthcare Reform Means You Can Have Your Care and Keep It Too 2
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Sodium in serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: